Astria Therapeutics, Inc. (NASDAQ:ATXS) Shares Sold by VR Adviser LLC

VR Adviser LLC lessened its holdings in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) by 29.0% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,457,348 shares of the biotechnology company’s stock after selling 1,001,297 shares during the quarter. Astria Therapeutics comprises about 1.5% of VR Adviser LLC’s holdings, making the stock its 18th biggest holding. VR Adviser LLC’s holdings in Astria Therapeutics were worth $21,969,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in ATXS. Fcpm Iii Services B.V. acquired a new stake in Astria Therapeutics in the fourth quarter valued at approximately $25,680,000. Vestal Point Capital LP raised its holdings in Astria Therapeutics by 4.5% in the fourth quarter. Vestal Point Capital LP now owns 4,180,000 shares of the biotechnology company’s stock valued at $37,369,000 after acquiring an additional 180,000 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Astria Therapeutics in the fourth quarter valued at approximately $707,000. Patient Square Capital LP raised its holdings in Astria Therapeutics by 166.5% in the fourth quarter. Patient Square Capital LP now owns 105,057 shares of the biotechnology company’s stock valued at $939,000 after acquiring an additional 65,635 shares in the last quarter. Finally, Voya Investment Management LLC raised its holdings in Astria Therapeutics by 367.4% in the fourth quarter. Voya Investment Management LLC now owns 71,708 shares of the biotechnology company’s stock valued at $641,000 after acquiring an additional 56,366 shares in the last quarter. Institutional investors and hedge funds own 98.98% of the company’s stock.

Astria Therapeutics Trading Up 7.6%

Shares of ATXS opened at $4.26 on Tuesday. The firm has a market cap of $240.41 million, a PE ratio of -2.04 and a beta of 0.45. The company’s 50 day simple moving average is $4.95 and its 200-day simple moving average is $7.29. Astria Therapeutics, Inc. has a 12-month low of $3.56 and a 12-month high of $12.92.

Astria Therapeutics (NASDAQ:ATXS) last announced its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.10). As a group, equities research analysts forecast that Astria Therapeutics, Inc. will post -1.65 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently weighed in on ATXS shares. Citizens Jmp raised shares of Astria Therapeutics to a “strong-buy” rating in a report on Friday, January 31st. JMP Securities started coverage on shares of Astria Therapeutics in a report on Friday, January 31st. They set an “outperform” rating and a $26.00 price objective on the stock. HC Wainwright reissued a “buy” rating and set a $16.00 price objective on shares of Astria Therapeutics in a report on Tuesday, March 11th. Cantor Fitzgerald reissued an “overweight” rating and set a $47.00 price objective on shares of Astria Therapeutics in a report on Wednesday, May 14th. Finally, Wedbush reissued an “outperform” rating and set a $28.00 price objective (up previously from $27.00) on shares of Astria Therapeutics in a report on Wednesday, March 12th. Six research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $30.00.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.